IGF-1 & Growth Hormone Axis: Peptide Research Guide

Introduction to the GH/IGF-1 Axis

The growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis represents one of the most critical endocrine signaling cascades in mammalian biology. This sophisticated neuroendocrine system governs growth, metabolism, body composition, tissue repair, and cellular regeneration throughout the lifespan. Understanding this axis is fundamental to comprehending how growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormone (GHRH) analogs, and related peptides exert their biological effects.

The GH/IGF-1 axis operates through a hierarchetical cascade: the hypothalamus releases GHRH, which stimulates pituitary somatotroph cells to secrete growth hormone. GH then acts on the liver and peripheral tissues to stimulate IGF-1 production. This seemingly simple pathway involves dozens of regulatory proteins, binding partners, receptors, and feedback mechanisms that create a remarkably precise control system. Research peptides that modulate this axis — including ipamorelin, CJC-1295, GHRP-6, GHRP-2, hexarelin, and sermorelin — have become essential tools for investigating GH biology and its downstream effects.

This comprehensive guide examines the molecular architecture of the GH/IGF-1 axis, how research peptides interact with each component, the complex feedback mechanisms that maintain homeostasis, and the implications for research into aging, metabolism, tissue repair, and body composition. We’ll explore current scientific understanding supported by peer-reviewed research, clinical trial data, and emerging discoveries that continue to reshape our knowledge of this fundamental biological system.

Hypothalamic Control: GHRH and Somatostatin

Growth Hormone-Releasing Hormone (GHRH)

GHRH, a 44-amino acid peptide produced in the arcuate nucleus of the hypothalamus, serves as the primary stimulatory signal for GH secretion. GHRH binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells, activating adenylyl cyclase through Gs? protein coupling. This increases intracellular cyclic AMP (cAMP), activating protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and ultimately stimulates GH gene transcription and secretion.

GHRH has a relatively short half-life of approximately 7-10 minutes in circulation due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). This short half-life is actually physiologically important — it allows for pulsatile GH release patterns rather than continuous stimulation. The pulsatile pattern of GH secretion (with major pulses occurring during slow-wave sleep) is critical for optimal biological function, as continuous GH exposure leads to receptor desensitization and diminished downstream signaling.

Research peptides based on the GHRH structure have been developed to overcome this rapid degradation. Sermorelin (GHRH 1-29) retains full biological activity using only the first 29 amino acids. CJC-1295 incorporates a Drug Affinity Complex (DAC) modification that extends its half-life to 6-8 days by binding to serum albumin, allowing sustained GHRH receptor activation. Modified GRF (1-29), also known as CJC-1295 without DAC or Mod GRF, uses amino acid substitutions at positions 2, 8, 15, and 27 to resist DPP-IV degradation while maintaining a shorter, more physiological half-life profile.

Somatostatin: The Inhibitory Counterpart

Somatostatin (SST), also called growth hormone-inhibiting hormone (GHIH), is produced primarily in the periventricular nucleus of the hypothalamus as well as in the gastrointestinal tract and pancreatic delta cells. The two bioactive forms — SST-14 and SST-28 — act through five somatostatin receptor subtypes (SSTR1-5) expressed on somatotroph cells and throughout the body.

Somatostatin’s role extends beyond simple GH inhibition. It suppresses GHRH release from the hypothalamus, inhibits GH secretion from the pituitary through direct action on somatotrophs, reduces hepatic IGF-1 production, and modulates the GH response to GHRH stimulation. The interplay between GHRH and somatostatin creates the ultradian rhythm of GH secretion — approximately 6-12 discrete GH pulses per 24 hours, with the largest pulses occurring during nighttime slow-wave sleep.

Understanding somatostatin’s role is crucial for peptide research because the timing of peptide administration relative to somatostatin tone significantly affects the GH response. Administering GH-releasing peptides during periods of high somatostatin tone (such as during waking hours after recent food intake) produces a blunted GH response compared to administration during somatostatin withdrawal periods.

Pituitary Somatotrophs: GH Synthesis and Secretion

Growth Hormone Structure and Variants

Human growth hormone (hGH) is a 191-amino acid, 22-kDa single-chain polypeptide with two disulfide bonds. The pituitary produces several GH variants through alternative splicing, with the 22-kDa form representing approximately 75% of circulating GH and the 20-kDa variant comprising most of the remainder. These variants may have distinct biological activities — the 20-kDa form appears to have reduced diabetogenic activity while retaining growth-promoting effects.

Somatotroph cells constitute approximately 35-45% of the anterior pituitary cell population and contain secretory granules loaded with pre-formed GH. Upon GHRH stimulation, calcium influx through voltage-gated calcium channels triggers exocytosis of these granules. The GH secretagogue receptor (GHS-R1a), which is the target of ghrelin and synthetic GH-releasing peptides like ipamorelin and GHRP-6, provides an additional stimulatory input that synergizes with GHRH signaling.

The GH Secretagogue Receptor (GHS-R1a)

The GHS-R1a receptor was identified in 1996 as a G protein-coupled receptor that mediates the GH-releasing effects of synthetic secretagogues. Its endogenous ligand, ghrelin, was subsequently discovered in 1999. This receptor signals through Gq/11 proteins, activating phospholipase C to produce inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from intracellular stores, while DAG activates protein kinase C (PKC).

This signaling pathway is distinct from and complementary to the GHRH/cAMP/PKA pathway, which explains the synergistic GH-releasing effect observed when GHRH analogs and GH secretagogues are co-administered. Research has demonstrated that combining a GHRH analog (such as CJC-1295 or Mod GRF 1-29) with a GHRP (such as ipamorelin) produces a GH response that is 2-3 times greater than either peptide alone. This synergy forms the basis for the widely researched ipamorelin + CJC-1295 stack.

Different synthetic GH secretagogues show varying selectivity and potency at the GHS-R1a receptor. Ipamorelin is notable for its high selectivity — it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels, unlike GHRP-6 and GHRP-2, which can stimulate these hormones at higher doses. Hexarelin is the most potent GHRP but shows the greatest propensity for cortisol and prolactin elevation. These pharmacological differences make each peptide useful for different research contexts.

IGF-1: The Primary Mediator of GH Actions

IGF-1 Structure and Synthesis

Insulin-like growth factor 1 (IGF-1) is a 70-amino acid polypeptide with structural homology to proinsulin. The liver is the primary source of circulating (endocrine) IGF-1, producing approximately 75% of the total blood IGF-1 in response to GH stimulation. However, virtually every tissue in the body produces IGF-1 locally (autocrine/paracrine IGF-1) in response to GH and other growth factors, and this local production is critical for tissue-specific growth and repair.

GH stimulates IGF-1 gene transcription through the GH receptor (GHR)/JAK2/STAT5b signaling pathway. When GH binds the GHR, it induces receptor dimerization and activation of the associated Janus kinase 2 (JAK2). JAK2 phosphorylates several substrates, including STAT5b (Signal Transducer and Activator of Transcription 5b), which dimerizes, translocates to the nucleus, and activates IGF-1 gene transcription. This pathway is essential — STAT5b knockout models show severely reduced IGF-1 levels and growth retardation.

IGF-1 exists in circulation primarily bound to IGF-binding proteins (IGFBPs), with IGFBP-3 being the most abundant. The ternary complex of IGF-1/IGFBP-3/acid-labile subunit (ALS) extends IGF-1’s half-life from approximately 10 minutes (free form) to 12-15 hours. This binding protein system serves as both a reservoir and a buffer, preventing the hypoglycemic effects that would occur if the full complement of circulating IGF-1 were in its free, bioactive form.

IGF-1 Receptor Signaling

The IGF-1 receptor (IGF-1R) is a transmembrane tyrosine kinase receptor structurally similar to the insulin receptor. Upon IGF-1 binding, the receptor autophosphorylates and activates two major downstream signaling cascades: the PI3K/Akt/mTOR pathway (primarily mediating metabolic and anti-apoptotic effects) and the Ras/Raf/MEK/ERK pathway (primarily mediating proliferative and differentiative effects).

The PI3K/Akt/mTOR pathway is particularly important for understanding IGF-1’s anabolic effects. Akt phosphorylation activates mTORC1 (mammalian target of rapamycin complex 1), which stimulates protein synthesis through phosphorylation of S6K1 and 4E-BP1. Simultaneously, Akt inhibits GSK3? and FOXO transcription factors, reducing protein degradation and promoting cell survival. This dual action — increasing protein synthesis while decreasing protein degradation — underlies IGF-1’s potent anabolic properties in muscle and other tissues.

The Ras/Raf/MEK/ERK pathway drives cellular proliferation and differentiation, which is essential for IGF-1’s growth-promoting effects. In bone, this pathway stimulates osteoblast proliferation and differentiation. In muscle, it contributes to satellite cell activation and myoblast proliferation. In the nervous system, ERK signaling mediates IGF-1’s neuroprotective and neuroplasticity effects.

IGF-1 Variants and Splice Isoforms

The IGF-1 gene produces several splice variants with distinct biological properties. The major isoforms include IGF-1Ea (liver-type or systemic IGF-1), IGF-1Eb, and IGF-1Ec (also known as mechano-growth factor or MGF in humans). MGF is particularly interesting in research contexts because it is upregulated by mechanical loading and exercise in skeletal muscle, suggesting a role in exercise-induced hypertrophy and repair.

These splice variants differ in their E-peptide domains, which are cleaved during post-translational processing to yield mature IGF-1. Research suggests that the E-peptides themselves may have independent biological activity — MGF E-peptide has been shown to activate satellite cells and promote muscle stem cell proliferation independently of mature IGF-1 signaling through the IGF-1R.

Feedback Mechanisms and Regulatory Loops

Negative Feedback Loops

The GH/IGF-1 axis is regulated by multiple negative feedback loops that maintain homeostatic control. IGF-1 feeds back at both the hypothalamic and pituitary levels. At the hypothalamus, IGF-1 stimulates somatostatin release and inhibits GHRH secretion. At the pituitary, IGF-1 directly suppresses GH gene transcription and secretion by somatotroph cells through activation of IGF-1R on somatotrophs.

GH itself participates in short-loop negative feedback by stimulating hypothalamic somatostatin release. This creates a self-limiting system where GH pulses are followed by refractory periods during which the pituitary is relatively unresponsive to GHRH stimulation. This refractory period is important for research peptide protocols — administering GHRPs during the refractory period following a previous GH pulse yields suboptimal responses.

Free fatty acids (FFAs) also provide important feedback inhibition of GH secretion. Elevated FFAs, such as those following a high-fat meal, suppress GH release through both central and peripheral mechanisms. This explains why fasting (which reduces circulating FFAs) potentiates GH secretion, and why many research protocols recommend fasted-state administration of GH-releasing peptides for maximum effect.

Positive Regulatory Inputs

Several factors amplify GH/IGF-1 axis activity. Ghrelin, produced primarily by gastric oxyntic cells during fasting, acts through GHS-R1a to stimulate GH release. Exercise, particularly resistance training and high-intensity interval training, acutely stimulates GH secretion through mechanisms that involve cholinergic pathways, catecholamine release, nitric oxide signaling, and direct effects on somatotroph cells.

Sleep, specifically slow-wave sleep (stages 3-4 of non-REM sleep), is the strongest natural stimulus for GH secretion. Approximately 50-70% of daily GH output occurs during nocturnal sleep pulses. This relationship is mediated by increased GHRH release and decreased somatostatin tone during slow-wave sleep, creating optimal conditions for maximal GH pulse amplitude. Sleep deprivation significantly blunts the nocturnal GH surge, and chronic sleep disruption can lead to measurably reduced IGF-1 levels.

Amino acids, particularly arginine, ornithine, and lysine, stimulate GH release through suppression of somatostatin tone. Arginine’s GH-releasing effect is well-documented in clinical testing — the arginine stimulation test is used diagnostically to assess pituitary GH reserve. This somatostatin-suppressive mechanism is complementary to the GHRH and GHRP pathways, which is why some research protocols combine arginine with GH-releasing peptides.

Research Peptides and the GH/IGF-1 Axis

GHRH Analogs

Sermorelin (GHRH 1-29): The first synthetic GHRH analog approved for diagnostic and therapeutic use. Sermorelin contains the minimum active fragment of GHRH and binds the GHRH receptor with full agonist activity. Its short half-life (approximately 10-12 minutes) makes it useful for studying acute GH release dynamics but limits its practical utility for sustained GH axis stimulation. Repeated daily administration has been shown to increase IGF-1 levels by 20-40% in research models.

CJC-1295 (with DAC): This modified GHRH analog incorporates a reactive chemical group that covalently binds to serum albumin after injection, extending its half-life to 6-8 days. Research demonstrates that single doses of CJC-1295 DAC can elevate IGF-1 levels for 6-14 days, with peak IGF-1 increases of 40-100% above baseline depending on dosage. However, the sustained GHRH receptor activation pattern differs from natural pulsatile stimulation.

Modified GRF 1-29 (CJC-1295 no DAC): Features four amino acid substitutions (Ala2, D-Ala8, Ala15, Leu27) that resist DPP-IV degradation while maintaining a shorter half-life of approximately 30 minutes. This allows for more physiological pulsatile GH stimulation compared to the DAC version, as each injection produces a discrete GH pulse rather than sustained tonic stimulation. Many research protocols prefer this form, particularly when combined with a GHRP.

Growth Hormone Releasing Peptides (GHRPs)

Ipamorelin: A pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that selectively activates GHS-R1a with minimal effects on cortisol, prolactin, and aldosterone. Research shows dose-dependent GH release with ED50 of approximately 80 nmol/kg in animal models. Ipamorelin’s selectivity profile makes it particularly valuable in research settings where isolating GH-specific effects is important. When combined with CJC-1295 no DAC, the synergistic effect produces robust GH pulses that more closely mimic physiological amplitudes.

GHRP-6: A hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that potently stimulates GH release through GHS-R1a activation. Unlike ipamorelin, GHRP-6 also stimulates appetite through ghrelin-mimetic effects and can elevate cortisol and prolactin at higher doses. It produces a stronger acute GH response than ipamorelin but with less selectivity. GHRP-6 is valuable in research studying the relationship between GH secretion and appetite/metabolism.

GHRP-2: Considered the most potent GHRP for GH release on a per-milligram basis. Like GHRP-6, it stimulates appetite and can affect cortisol and prolactin levels. GHRP-2 shows strong synergy with GHRH analogs and has been extensively studied in clinical trials for its effects on body composition, sleep architecture, and metabolic parameters.

Hexarelin: The most potent GH secretagogue but also the most non-selective, with significant effects on cortisol, prolactin, and ACTH. Hexarelin is notable for its cardiac effects — research has identified direct cardioprotective properties mediated through CD36 receptors independent of GH release. Hexarelin also shows tachyphylaxis (diminished response with repeated dosing) more rapidly than other GHRPs.

Combination Protocols in Research

The most widely studied peptide combinations for GH/IGF-1 axis modulation involve pairing a GHRH analog with a GHRP. The scientific rationale is clear: GHRH analogs activate the cAMP/PKA pathway in somatotrophs, while GHRPs activate the PLC/PKC/calcium pathway through GHS-R1a. These distinct signaling cascades converge to produce an amplified GH secretory response that exceeds the sum of individual peptide effects.

Research data consistently shows that the combination of Mod GRF 1-29 + ipamorelin produces GH pulses with amplitudes 2-3 times greater than either peptide alone. The ipamorelin component also functionally antagonizes somatostatin’s inhibitory tone on somatotrophs, partially overriding the natural brake on GH secretion. This combination has become the reference standard in GH peptide stack research due to its favorable efficacy-to-selectivity ratio.

Timing of administration is critical in these protocols. Research suggests that peptide-stimulated GH release is greatest during periods of low somatostatin tone — typically in the fasted state and at bedtime. Post-meal administration, particularly after carbohydrate or fat-rich meals, significantly blunts the GH response due to elevated somatostatin, insulin, and free fatty acids. Most research protocols specify administration 2-3 hours after the last meal.

Age-Related Changes in the GH/IGF-1 Axis

The Somatopause

GH secretion declines progressively with aging at a rate of approximately 14% per decade after age 30. By age 60-70, mean 24-hour GH concentrations are approximately 30-50% of young adult levels. This age-related decline in GH secretion — termed the “somatopause” — is accompanied by proportional decreases in circulating IGF-1 levels and is associated with changes in body composition, bone density, cognitive function, and metabolic health that characterize aging.

The mechanisms underlying the somatopause are multifactorial. Key changes include: increased somatostatin tone (reducing GH pulse amplitude), decreased GHRH production and secretion, reduced somatotroph cell number and GH content, increased adiposity (which itself suppresses GH through elevated FFAs and insulin), and decreased ghrelin sensitivity. Importantly, the pituitary retains the capacity to secrete GH in response to strong stimulation — the somatopause reflects primarily a neuroendocrine regulatory shift rather than pituitary failure.

This retained pituitary capacity is the basis for using GH-releasing peptides in aging research. Studies demonstrate that elderly subjects respond to GHRH and GHRP stimulation with significant GH release, although the absolute response is typically lower than in young adults. Combination protocols (GHRH + GHRP) partially overcome the age-related resistance, producing GH pulses in elderly subjects that approach those seen in younger individuals.

IGF-1 Decline and Aging Biomarkers

Circulating IGF-1 levels decline approximately 20-40% between ages 20 and 80. Low IGF-1 levels in the elderly are associated with reduced muscle mass (sarcopenia), decreased bone mineral density (osteoporosis), increased visceral adiposity, impaired cognitive function, reduced cardiovascular fitness, and decreased wound healing capacity. However, the relationship between IGF-1 and longevity is complex and somewhat paradoxical.

Research in model organisms has consistently shown that reduced GH/IGF-1 signaling extends lifespan — Ames dwarf mice and GH receptor knockout mice live 30-70% longer than wild-type animals. Similarly, human centenarian studies have identified overrepresentation of genetic variants associated with reduced IGF-1 signaling. This creates an apparent paradox: low IGF-1 is associated with both aging-related disease and extended longevity.

Current research suggests that the relationship between IGF-1 and health follows a U-shaped curve, with both very low and very high IGF-1 levels associated with increased mortality risk. The optimal range may depend on tissue-specific context — sufficient IGF-1 for tissue maintenance and repair, but not excessive levels that promote cellular proliferation beyond what is needed. This nuanced view has important implications for research into GH-releasing peptides and anti-aging peptide strategies.

IGF-1 in Tissue-Specific Research

Skeletal Muscle

IGF-1 is a critical regulator of skeletal muscle mass through its effects on protein synthesis, protein degradation, and satellite cell dynamics. Muscle-specific IGF-1 overexpression in animal models produces significant hypertrophy and maintains muscle mass during aging, demonstrating the importance of local IGF-1 signaling independently of systemic levels.

In muscle tissue, IGF-1R activation triggers the PI3K/Akt/mTOR cascade, stimulating protein synthesis through increased ribosomal biogenesis and translation initiation. Simultaneously, Akt phosphorylates and inactivates FOXO transcription factors, reducing expression of the E3 ubiquitin ligases atrogin-1/MAFbx and MuRF1, which are primary mediators of proteasomal protein degradation in muscle. This dual mechanism — enhanced synthesis plus reduced degradation — explains IGF-1’s potent anabolic effects.

MGF (mechano-growth factor), the exercise-responsive IGF-1 splice variant, activates muscle satellite cells — the resident stem cells responsible for muscle regeneration and adaptive hypertrophy. After resistance exercise, local MGF expression increases rapidly (within hours), preceding the delayed increase in IGF-1Ea expression. This temporal sequence suggests that MGF initiates the repair/adaptation response while sustained IGF-1Ea signaling supports the subsequent growth phase.

Bone

The GH/IGF-1 axis is essential for skeletal development, bone remodeling, and fracture repair. GH and IGF-1 stimulate osteoblast proliferation and differentiation while modulating osteoclast activity. Liver-derived endocrine IGF-1 contributes approximately 25-30% to bone’s IGF-1 supply, with the remainder produced locally by osteoblasts and bone marrow stromal cells.

IGF-1 promotes bone formation through several mechanisms: stimulating type I collagen synthesis (the primary organic component of bone matrix), increasing alkaline phosphatase activity, promoting osteoblast survival by suppressing apoptosis through Akt signaling, and enhancing osteoblast differentiation through MAPK/ERK pathway activation. IGF-1R signaling also modulates the RANKL/OPG ratio, indirectly influencing osteoclast formation and bone resorption.

Brain and Nervous System

IGF-1 crosses the blood-brain barrier through a saturable transport mechanism and exerts significant neurotrophic, neuroprotective, and neuroplasticity effects. Brain IGF-1R signaling promotes neuronal survival, axonal growth, myelination, synaptic plasticity, and adult neurogenesis in the hippocampus. These effects have generated interest in the GH/IGF-1 axis as a target for research into neurodegenerative conditions and cognitive aging.

Exercise-induced increases in circulating IGF-1 correlate with improved hippocampal neurogenesis and cognitive performance in animal models. GH-releasing peptides that elevate both GH and IGF-1 may therefore have research implications beyond traditional growth and metabolism studies. The relationship between GH/IGF-1 axis activity, sleep quality, and cognitive function represents an active area of investigation.

Measuring the GH/IGF-1 Axis in Research

GH Measurement Challenges

Measuring GH in research is complicated by its pulsatile secretion pattern, short circulating half-life (15-20 minutes), multiple molecular forms, and significant variation in assay methodologies. A single random GH measurement is essentially meaningless because values can range from undetectable to peaks of 20-30+ ng/mL within minutes during a secretory pulse.

Research approaches to GH measurement include: 24-hour serial sampling (every 10-20 minutes to capture the full pulsatile profile), stimulation tests (GHRH, arginine, insulin tolerance, GHRP challenges), and measurement of 24-hour urinary GH excretion. Each method has advantages and limitations, and the choice depends on the research question being addressed.

IGF-1 as a Surrogate Marker

Because IGF-1 has a much longer half-life (12-15 hours in the ternary complex) and relatively stable circulating levels, it serves as a more practical surrogate marker for integrated GH secretory status. A single fasting IGF-1 measurement provides a reasonable estimate of the previous 24-48 hours of GH secretory activity, making it the preferred clinical and research biomarker for GH axis assessment.

IGF-1 reference ranges are age- and sex-dependent, with peak levels during puberty (typically 300-600 ng/mL in mid-puberty) declining to adult ranges (typically 100-300 ng/mL depending on age and assay). Research involving GH-releasing peptides typically uses serial IGF-1 measurements (baseline, weekly or biweekly during the protocol, and post-protocol) to assess the integrated effect on GH/IGF-1 axis output.

IGFBP-3 measurement provides additional information, as it is also GH-dependent and carries most circulating IGF-1. The IGF-1/IGFBP-3 molar ratio can provide an estimate of free (bioactive) IGF-1. Some research protocols also measure the acid-labile subunit (ALS), another GH-dependent protein, for a more complete assessment of axis activity.

Clinical Research Applications

Body Composition Research

GH/IGF-1 axis modulation through peptides has been extensively studied for effects on body composition. GH promotes lipolysis (fat breakdown) through hormone-sensitive lipase activation, particularly in visceral adipose tissue. Simultaneously, IGF-1 promotes protein accretion in lean tissues. This dual effect — reducing fat while preserving or increasing lean mass — has made GH-releasing peptides important tools in body composition research.

Research with tesamorelin, a GHRH analog, has demonstrated significant visceral adipose tissue reduction (approximately 15-18%) in clinical trials studying HIV-associated lipodystrophy. These studies provide the strongest clinical evidence for peptide-mediated GH axis activation affecting body composition. Similar but smaller-scale studies with other GH-releasing peptides support the generalizability of this effect across different peptide classes.

Sleep and Recovery Research

The intimate relationship between the GH/IGF-1 axis and sleep has generated research interest in bidirectional effects. GH-releasing peptides administered before sleep may enhance slow-wave sleep duration, increase nocturnal GH pulse amplitude, and improve subjective sleep quality. GHRP-2, in particular, has been studied for its effects on sleep architecture, with research showing increased slow-wave sleep duration and enhanced sleep-related GH secretion.

The recovery implications are significant: slow-wave sleep is the period of maximal tissue repair, and GH/IGF-1 signaling during this phase supports protein synthesis, immune function, and tissue regeneration. Research protocols examining the effects of GH-releasing peptides on recovery from exercise, injury, or surgical procedures often incorporate sleep assessment as a primary or secondary outcome measure.

Frequently Asked Questions

What is the GH/IGF-1 axis?

The GH/IGF-1 axis is a neuroendocrine signaling cascade where the hypothalamus releases GHRH (stimulatory) and somatostatin (inhibitory), the pituitary produces growth hormone (GH), and the liver and peripheral tissues produce IGF-1 in response to GH. This system regulates growth, metabolism, body composition, tissue repair, and cellular regeneration throughout life. Feedback loops at multiple levels maintain homeostatic control of the axis.

How do GH-releasing peptides increase IGF-1?

GH-releasing peptides (GHRPs) stimulate the pituitary to release GH by activating the GH secretagogue receptor (GHS-R1a). The released GH then travels to the liver and other tissues where it activates the GH receptor/JAK2/STAT5b pathway, stimulating IGF-1 gene transcription and protein production. The resulting increase in circulating IGF-1 mediates many of GH’s biological effects. The magnitude of IGF-1 increase depends on the peptide type, dose, and individual factors.

Why combine GHRH analogs with GHRPs?

GHRH analogs and GHRPs activate different signaling pathways in pituitary somatotroph cells — GHRH uses the cAMP/PKA pathway while GHRPs use the PLC/PKC/calcium pathway. These distinct pathways converge synergistically, producing GH pulses 2-3x greater than either peptide alone. Additionally, GHRPs partially overcome somatostatin’s inhibitory tone, further amplifying the GH response. This synergy makes the combination more effective than higher doses of either peptide individually.

Does the GH/IGF-1 axis decline with age?

Yes. GH secretion declines approximately 14% per decade after age 30, a process called the somatopause. By age 60-70, GH levels are 30-50% of young adult values, with proportional IGF-1 decline. This is caused by increased somatostatin tone, decreased GHRH production, reduced pituitary GH stores, and increased adiposity. However, the pituitary retains the capacity to respond to strong stimulation, which is why GH-releasing peptides can still elicit significant GH release in older subjects.

What is the difference between endocrine and autocrine/paracrine IGF-1?

Endocrine IGF-1 is produced mainly by the liver and circulates in the bloodstream to act on distant tissues. Autocrine/paracrine IGF-1 is produced locally within tissues (muscle, bone, brain, etc.) and acts on nearby cells. While liver-derived IGF-1 accounts for approximately 75% of circulating levels, local IGF-1 production is critical for tissue-specific growth, repair, and maintenance. Research suggests that local IGF-1 may be more important than circulating IGF-1 for certain tissue-specific effects.

Disclaimer: This article is for informational and educational purposes only. All peptides mentioned are sold strictly for laboratory research use. This content does not constitute medical advice. Consult qualified healthcare professionals for any health-related decisions.